HIGHLIGHTS
- who: Yunchao Wang et al. from the Southwest Medical University, China have published the research: Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC, in the Journal: (JOURNAL) of March/19,/2019
- what: The authors assessed the safety and feasibility of RT plus toripalimab and lenvatinib in patients with advanced BTC. The authors acknowledge that this study has some limitations.
SUMMARY
The response rates of either PD-1/PD-L1 inhibitors alone or PD-1/PD-L1 inhibitors with targeted therapies remain less than ideal in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.